ScreenerHero

DRUG Bright Minds Biosciences Inc.

NAS · US · Healthcare · Biotechnology · brightmindsbio.com
52.00USD+7.77%Mkt Cap: 512.93M $P/E: —

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which ar…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap512.93M USD
Enterprise Value168.18M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.23M USD
Revenue/Share—
Last Price52.00 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees26
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.39
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.17
EPS (TTM)-2.05
EPS (Forward)-5.75
52W Range
47.356% of range123.75
52W High123.75 USD
52W Low47.35 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-14.91%
ROA-14.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.69M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-3.66%
Net Debt-307.76M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio121.97
Quick Ratio121.44
Book Value/Sh22.29 USD
Cash/Share31.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateJul 14, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)152.42 USD
Upside (mean)+193.1%
Target Range122.90 USD – 220.45 USD
122.90+193.1% to mean220.45
# Analysts6
Ownership
Shares Out.9.86M
Float6.69M
Insiders11.94%
Institutions94.95%
Short Interest
Short Ratio8.9d
Short % Float12.24%
Short % Out.9.45%
Shares Short931.94K
Short (prev mo.)897.28K
Technical
SMA 5068.60 (-24.2%)
SMA 20076.32 (-31.9%)
Beta0.23
S&P 52W Chg16.45%
Avg Vol (30d)121.23K
Avg Vol (10d)114.25K
Technical Indicators
RSI (14)34.8
MACD-5.6638
MACD Signal-5.6158
MACD Hist.-0.0480
BB Upper69.22 USD
BB Middle56.46 USD
BB Lower43.71 USD
BB Width45.18%
ATR (14)3.401 USD
Vol Ratio (20d)6.92x